Objective To assess real-world comparative effectiveness studies of biologic (b) and
targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs) in adults with …

Objectives Target trial emulation is an intuitive design framework that encourages
investigators to formulate their comparative effectiveness research (CER) question as a …

Background Lymphomas comprise a heterogeneous group of malignant diseases with
highly variable prognosis. Rheumatoid arthritis (RA) is associated with a twofold increased …

Background The use of TNF-inhibitors and/or the IL-6 receptor antagonist, tocilizumab, in
rheumatoid arthritis (RA) have pleiotropic effects that also involve circulating B-cells. The …

Objectives Current guidelines rank abatacept, rituximab, tocilizumab and TNF-inhibitors
(TNFi) as having equal effectiveness for the treatment of RA, at least as second line …

Introduction Timely matching of patients to beneficial targeted therapy is an unmet need in
rheumatoid arthritis (RA). A molecular signature response classifier (MSRC) that predicts …

Objective To compare clinical effectiveness between tocilizumab and tumor necrosis factor
inhibitors (TNFi) in patients with rheumatoid arthritis (RA) and inadequate response to …

To assess the long-term effectiveness and safety of tocilizumab, abatacept, and tumor
necrosis factor-α inhibitors (TNFi), in the Italian real-world setting of rheumatoid arthritis …

The aim of this study was to investigate the influence of clinical and genetic factors on
response to tocilizumab (TCZ) response, remission, low disease activity (LDA) and DAS28 …

In the present study, we aimed to investigate the influence of clinical parameters and single-
nucleotide polymorphisms of interleukin-6 receptor (rs12083537, rs2228145, rs4329505 …